Literature DB >> 16925770

The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis.

Essam M Elsamman1, Tomoharu Fukumori, Shuji Tanimoto, Ryoichi Nakanishi, Masayuki Takahashi, Kazunori Toida, Hiro-Omi Kanayama.   

Abstract

OBJECTIVES: To analyse the gene expression level of prostate stem cell antigen (PSCA) in human clear cell renal cell carcinoma (CC-RCC) and its relationship with conventional clinicopathological manifestations, to evaluate its prognostic value for patient outcome, and to determine the effect of PSCA on the progression of CC-RCC. PATIENTS AND METHODS: We quantified PSCA mRNA level in human RCC cell lines (ACHN, A704, KPK-1, Caki-1, and Caki-2) and in 154 surgical tissue samples (81 from CC-RCC, 73 from normal kidney) using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The findings were analysed in relation to clinicopathological factors. Immunohistochemical expression was examined using confocal laser scanning light-microscopy.
RESULTS: PSCA was overexpressed in all RCC cell lines. PSCA mRNA levels were significantly higher in CC-RCC than in normal kidney tissue samples (P < 0.001), in G2-G3 than in G1 tumours (P = 0.028), and in advanced disease (T3-T4) than in organ-confined (T1-T2) tumours (P = 0.016). There was significantly higher PSCA mRNA expression in patients with M1 than in those with M0 disease (P = 0.029). Patients in whom the lesions had high PSCA expression levels had a significantly worse prognosis than those with low PSCA expression levels (P = 0.044). Using immunohistochemical analysis there was markedly greater PSCA expression in CC-RCC than in normal kidney, and in advanced-disease high-grade tumours than in organ-confined low-grade tumours.
CONCLUSIONS: A significant correlation was detected in the gene expression level of PSCA with histological grade, clinicopathological stage and prognosis in CC-RCC. Our data indicate that PSCA is associated with carcinogenesis and progression of CC-RCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16925770     DOI: 10.1111/j.1464-410X.2006.06350.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

Review 1.  Prostate stem cell antigen: a Jekyll and Hyde molecule?

Authors:  Norihisa Saeki; Jian Gu; Teruhiko Yoshida; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

2.  Effects of PSCA rs2294008 (C/T) and c-MYC rs9642880 (G/T) polymorphisms on bladder cancer: evidence from a meta-analysis.

Authors:  Jie Gao; Peng-Tao Yang; Yan Diao; Hua-Feng Kang; Yang Zhao; Shuai Lin; Zi-Ming Wang; Meng Wang; Xi-Jing Wang; Zhi-Jun Dai
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 3.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

4.  The PSCA polymorphisms derived from genome-wide association study are associated with risk of gastric cancer: a meta-analysis.

Authors:  Danni Shi; Shizhi Wang; Dongying Gu; Dongmei Wu; Meilin Wang; Haiyan Chu; Na Tong; Lan Ma; Dongyan Zhong; Zhengdong Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-06       Impact factor: 4.553

Review 5.  Prostate stem cell antigen: a prospective therapeutic and diagnostic target.

Authors:  Adam B Raff; Andrew Gray; W Martin Kast
Journal:  Cancer Lett       Date:  2008-10-05       Impact factor: 8.679

6.  Prostate stem cell antigen gene TT genotype and development of intestinal metaplasia in Helicobacter pylori infection.

Authors:  Takahiro Uotani; Mitsushige Sugimoto; Hitomi Ichikawa; Shingo Tanaka; Hiroyuki Nagashima; Tomohisa Uchida; David Y Graham; Yoshio Yamaoka
Journal:  J Dig Dis       Date:  2016-01       Impact factor: 2.325

7.  Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individuals.

Authors:  Paul Lochhead; Bernd Frank; Georgina L Hold; Charles S Rabkin; Michael T H Ng; Thomas L Vaughan; Harvey A Risch; Marilie D Gammon; Jolanta Lissowska; Melanie N Weck; Elke Raum; Heiko Müller; Thomas Illig; Norman Klopp; Alan Dawson; Kenneth E McColl; Hermann Brenner; Wong-Ho Chow; Emad M El-Omar
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

8.  Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors.

Authors:  Willi Jugel; Achim Aigner; Susanne Michen; Alexander Hagstotz; Alexander Ewe; Dietmar Appelhans; Gabriele Schackert; Achim Temme; Stefanie Tietze
Journal:  Pharmaceutics       Date:  2021-05-08       Impact factor: 6.321

9.  Missense allele of a single nucleotide polymorphism rs2294008 attenuated antitumor effects of prostate stem cell antigen in gallbladder cancer cells.

Authors:  Hiroe Ono; Dai Chihara; Fumiko Chiwaki; Kazuyoshi Yanagihara; Hiroki Sasaki; Hiromi Sakamoto; Hideo Tanaka; Teruhiko Yoshida; Norihisa Saeki; Keitaro Matsuo
Journal:  J Carcinog       Date:  2013-03-16

10.  Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.

Authors:  Indu Kohaar; Patricia Porter-Gill; Petra Lenz; Yi-Ping Fu; Adam Mumy; Wei Tang; Andrea B Apolo; Nathaniel Rothman; Dalsu Baris; Alan R Schned; Kris Ylaya; Molly Schwenn; Alison Johnson; Michael Jones; Masatoshi Kida; Debra T Silverman; Stephen M Hewitt; Lee E Moore; Ludmila Prokunina-Olsson
Journal:  J Natl Cancer Inst       Date:  2012-12-23       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.